Injectable Drug Delivery Market Set To Be Worth of $574.8 Billion by the Year 2020

The report "Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), End User (Hospital, Home Care Setting) - Global Forecast to 2020", the Injectable Drug Delivery market is expected to reach $574.8 Billion by 2020 from $326.1 Billion in 2015, growing at a CAGR of 12.0% from 2015 to 2020.

Browse 217 tables and 47 figures spread through 241 pages and in-depth TOC on "Injectable Drug Delivery Market"
Early buyers will receive 10% customization on this report.

Becton, Dickinson and Company (BD) (U.S.), Baxter International, Inc. (U.S.), Gerresheimer AG (Germany), Pfizer, Inc. (U.S.), Schott AG (Germany), Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel), and Eli Lilly and Company (U.S.) are the major players in the injectable drug delivery market.

Becton, Dickinson and Company (BD) dominated the injectable drug delivery market in 2014. The company offers an exhaustive product portfolio comprising pen injectors, auto injectors, auto-disable injection systems, and conventional injections.  Becton, Dickinson and Company’s well-established brand and its experience of nearly a decade in the market give it a competitive edge over other players. The company focuses on expanding its market share through its diverse product portfolio in the injectable drug delivery market. In March 2015, BD (U.S.) acquired CareFusion Corp (U.S.). This acquisition expanded the company’s product offerings and strengthened its presence in the market.

Ask For PDF Brochure:

In 2014, new product launches accounted for the largest share of the total number of strategic developments undertaken by market players. For instance, in May 2015, Eli Lilly and Company received U.S. FDA approval for Humalog 200 units/mL KwikPen (insulin lispro 200 units/mL; U-200), a prefilled syringe used for the treatment of type 1 and type 2 diabetes. This approval helped the company in providing a more efficient pen injection, in terms of the usage period. In April 2015, Teva Pharmaceutical Industries Ltd. launched the Argatroban injection for intravenous infusion, in the U.S. This injection is used as a blood thinner for adult patients. Through this launch, the company expanded its offerings in the U.S. market. In August 2014, Baxter International, Inc. received U.S. FDA approval for FLEXBUMIN [Albumin (Human)], USP, 5% Solution. It is a sterile, non-pyrogenic preparation of albumin in a single-dosage form for intravenous administration. FLEXBUMIN is used for the treatment of hypovolemia and hypoalbuminemia. This approval helped the company expand its injectable product offerings.

Asia is expected to be the fastest-growing country in the injectable drug delivery market. High growth in this market can be attributed to the increased demand for injectable insulin and self-injection devices, particularly pen injectors which are used in the treatment of diabetes.

Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise basic views on key players in the injectable drug delivery market and product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future.

Request To Get The Sample Copy Of This Report:

The other key strategies adopted by players in the injectable drug delivery market include agreements, collaborations, mergers & acquisitions, and expansion. These strategies were majorly adopted by Becton, Dickinson and Company (BD) (U.S.), Baxter International, Inc. (U.S.), Pfizer, Inc. (U.S.), Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel), and Eli Lilly and Company (U.S.).

Browse Related Reports:
Pen Needles Market
by Type (Standard and Safety), Needle Length (4mm, 5mm, 6mm, 8mm, 10mm, and 12mm), Therapy (Insulin, Glucagon-like peptide, Growth Hormones) - Analysis & Global Forecast to 2019.

Cannula Market by Product (Nasal, Arterial, Arthroscopy, Ophthalmic, Cardioplegia, Suction, Femoral, Injector, Infusion, Venous, Microcannula), Material (Plastic, Metal) & End User (Hospitals, Ambulatory Surgical Centers) - Global Forecast to 2020.

About MarketsandMarkets:
MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Subscribe Reports from Healthcare Domain @

Mr. Rohan

Unit No. 802, 8th Floor,
Tower - 7, Magarpatta City SEZ,
Hadapsar, Pune – 411013,
Maharashtra, India.
Tel: +1-888-6006-441.
Visit MarketsandMarkets Blog @
Connect with us on LinkedIn @